Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.58 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | UPP1 | Q16831 | 5/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3797196 | 0.81 | KDM4E (0.68) | ATMKDM4EALDH1A1HPGDUPP1 | |
| SCHEMBL13075980 | 0.81 | ATM (0.68) | ATMKDM4EALDH1A1HPGDUPP1 | |
| SCHEMBL1694758 | 0.76 | KDM4E (0.61) | ATMKDM4EALDH1A1HPGDUPP1 | |
| SCHEMBL8471827 | 0.76 | KDM4E (1.00) | ATMKDM4EALDH1A1HPGDUPP1 | |
| SCHEMBL16398184 | 0.76 | KDM4E (0.61) | ATMKDM4EALDH1A1HPGDUPP1 | |
| SCHEMBL3794931 | 0.73 | KDM4E (0.64) | ATMKDM4EALDH1A1HPGDUPP1 | |
| SCHEMBL10815675 | 0.72 | KDM4E (0.56) | ATMKDM4EALDH1A1HPGDUPP1 | |
| SCHEMBL4919077 | 0.72 | ATM (0.55) | ATMKDM4EALDH1A1HPGDUPP1 | |
| SCHEMBL10857081 | 0.71 | ATM (0.54) | ATMKDM4EALDH1A1HPGDUPP1 | |
| SCHEMBL16334999 | 0.71 | POLB (0.58) | ATMKDM4EALDH1A1HPGDUPP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2025-05-29 | — | — | US | disclosed |
| US-12168016-B2 | Aryl-OR heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-12168015-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-17 | — | — | US | disclosed |
| US-12161645-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240277723-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2024-08-22 | — | — | US | disclosed |
| US-20240245697-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2024-07-25 | — | — | US | disclosed |
| US-20240245698-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2024-07-25 | — | — | US | disclosed |
| EP-4360712-A2 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-3943485-B1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2023-12-27 | — | — | EP | disclosed |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | ABBVIE INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-20150353494-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2015-12-10 | — | — | US | disclosed |
| US-9090562-B2 | Aryl- or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140288041-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | Epizyme, Inc. (US) | 2014-09-25 | — | — | US | disclosed |
| US-8765732-B2 | Aryl- or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130123234-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-05-16 | — | — | US | disclosed |
| US-8410088-B2 | Aryl- or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120264734-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | Epizyme, Inc. | 2012-10-18 | — | — | US | disclosed |
| EP-0104876-B1 | HERBICIDAL CYCLOHEXANE-1,3-DIONE DERIVATIVES | ICI AUSTRALIA LIMITED (AU) | 1991-12-27 | — | — | EP | disclosed |
| US-4631081-A | Herbicidal cyclohexane-1,3-dione derivatives | ICI AUSTRALIA LIMITED (AU) | 1986-12-23 | — | — | US | disclosed |
| EP-0104876-A2 | Herbicidal cyclohexane-1,3-dione derivatives | ICI AUSTRALIA LIMITED (AU) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168016-B2 | Aryl-OR heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | ATM 2772/4885KDM4E 753/4885ALDH1A1 324/4885 |
| US-20240245698-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | ATM 2772/4885KDM4E 753/4885ALDH1A1 324/4885 |
| US-20240277723-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | ATM 2772/4885KDM4E 753/4885ALDH1A1 324/4885 |
| US-20150353494-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | ATM 2772/4885KDM4E 753/4885ALDH1A1 324/4885 |
| US-12161645-B2 | Aryl-or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | ATM 2772/4885KDM4E 753/4885ALDH1A1 324/4885 |
| US-20250170138-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | ATM 2772/4885KDM4E 753/4885ALDH1A1 324/4885 |
| US-20120264734-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | AHR, ARNT, CYP1B1 | ATM 2772/4885KDM4E 753/4885ALDH1A1 324/4885 |
| US-20240245697-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | ATM 2772/4885KDM4E 753/4885ALDH1A1 324/4885 |
| US-20140288041-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | AHR, ARNT, CYP1B1 | ATM 2772/4885KDM4E 753/4885ALDH1A1 324/4885 |
| US-20130123234-A1 | Aryl- or Heteroaryl-Substituted Benzene Compounds | AHR, ARNT, CYP1B1 | ATM 2772/4885KDM4E 753/4885ALDH1A1 324/4885 |
| US-20230066771-A1 | NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1H2, NR5A2 | ATM 4685/4885KDM4E 1833/4885ALDH1A1 940/4885 |
| US-12168015-B2 | Aryl-or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | ATM 2772/4885KDM4E 753/4885ALDH1A1 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.